Novo Nordisk, the Denmark-based Ozempic creator, has launched a bidding war with Pfizer Inc. to acquire New York-based Metsera Inc.
Founded in 2022, Metsera is a clinical-stage biopharmaceutical firm specializing in treatments for obesity and metabolic diseases.
In an Oct. 30 statement, Novo Nordisk confirmed it had submitted an unsolicited proposal to acquire Metsera. The company stated that the acquisition would complement its goals of developing new and different drugs for the treatment of millions more people worldwide who are living with obesity, diabetes, and their associated co-moridities.
Novo Nordisk’s proposal comes on the heels of a Sept. 22 announcement by both Metsera Inc. and Pfizer, Inc., stating they had entered into a definitive agreement for Pfizer to acquire Metsera. Headquartered in New York City, Pfizer touted the acquisition as a catalyst for accelerating “the next generation of medicines for obesity and cardiometabolic diseases.”…